Candles longidaza in gynecology. "Longidaza": reviews, release form, indications, instructions for use Longidaza suppositories composition

A drug with proteolytic activity.

A drug: LONGIDAZE ® (LONGIDAZE ®)

Active ingredient: bovhyaluronidase azoximer
ATX code: V03AX
KFG: A drug with proteolytic activity
ICD-10 codes (indications): A15, J63, J84, J90, K66.0, L94.0, N30, N35, N40, N41, N48, N71, N85.6, N97, N99.4, T14.0, T14.1
Reg. number: LSR-002940/07
Date of registration: 01.10.07
The owner of the reg. acc.: NPO PETROVAKS PHARM (Russia)

PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING

◊ Suppositories vaginal and rectal torpedo-shaped, light yellow in color, with a slight specific smell of cocoa butter, marbling is allowed.

Cocoa butter - to obtain a suppository weighing 1.3 g.

5 pieces. - cellular contour packings (1) - packs of cardboard.
5 pieces. - cellular contour packings (2) - packs of cardboard.
5 pieces. - cellular contour packings (4) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.
The description of the drug was approved by the manufacturer in 2017.

PHARMACHOLOGIC EFFECT

Longidase ® has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory action.

Prolonged action is achieved by covalent binding of the enzyme to a physiologically active polymeric carrier (azoxymer). Longidase ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and TNFα), increases the humoral immune response and the body's resistance to infection.

Pronounced antifibrotic properties of Longidase ® are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors: the enzymatic activity of Longidase ® is maintained when heated to 37°C for 20 days, while native hyaluronidase in the same conditions begins to lose its activity during the day.

Longidase ® provides simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier capable of binding enzyme inhibitors released during hydrolysis of matrix components and stimulators of collagen synthesis (iron ions, copper ions, heparin and others). Due to these properties, Longidase ® has not only the ability to depolymerize the connective tissue matrix in fibrous-granulomatous formations, but also to suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

Glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix, are a specific substrate for testicular hyaluronidase. As a result of depolymerization (breaking the bond between C 1 acetylglycosamine and C 4 glucuronic or induric acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, elasticity increases connective tissue, which manifests itself in a decrease in tissue swelling, flattening of scars, an increase in the range of motion of the joints, a decrease in contractures and prevention of their formation, and a decrease in the adhesive process.

Biochemical, immunological, histological and electron microscopic studies have shown that Longidase ® does not damage normal connective tissue, but causes destruction of the connective tissue changed in composition and structure in the area of fibrosis.

Longidase ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The drug is well tolerated by patients, no local and general allergic reactions were noted.

The use of the drug Longidase ® in therapeutic doses during or after surgical treatment does not cause deterioration of the course of the postoperative period or progression of the infectious process; does not slow down the recovery of bone tissue.

PHARMACOKINETICS

Suction and distribution

An experimental study of pharmacokinetics made it possible to establish that after rectal administration, Longidaza ® is characterized by a high distribution rate in the body, is well absorbed into the systemic circulation and reaches Cmax in the blood after 1 hour. The bioavailability of Longidaza ® upon rectal administration is high - about 90%.

The half-life is about 0.5 hours. The drug penetrates into all organs and tissues (including through the BBB and the hemato-ophthalmic barrier). Does not accumulate in tissues.

breeding

T 1/2 from 42 hours to 84 hours. Excreted mainly by the kidneys.

INDICATIONS

Adults and adolescents over 12 years of age as monotherapy and as part of complex therapy for diseases accompanied by connective tissue hyperplasia (including against the background of an inflammatory process).

In urology:

Chronic prostatitis;

Interstitial cystitis;

Strictures of the urethra and ureters;

Peyronie's disease;

The initial stage of benign prostatic hyperplasia;

Prevention of scarring and strictures after surgical interventions on the urethra, bladder, ureters.

In gynecology:

Prevention and treatment of adhesions in the pelvis in chronic inflammatory diseases internal genital organs;

Prevention and treatment of adhesions in the small pelvis after gynecological manipulations (including artificial abortions, previous surgical interventions on the pelvic organs);

Intrauterine synechia;

Tubal-peritoneal infertility;

Chronic endomyometritis.

In dermatovenereology:

Limited scleroderma;

Prevention of fibrotic complications of sexually transmitted infections.

In surgery:

Prevention and treatment of adhesions after surgical interventions on the abdominal organs;

Long-term non-healing wounds.

In pulmonology and phthisiology:

pneumofibrosis;

Siderosis;

Tuberculosis (cavernous-fibrous, infiltrative, tuberculoma);

Interstitial pneumonia;

fibrosing alveolitis;

Pleurisy.

To increase bioavailability antibiotic therapy in urology, gynecology, dermatovenereology, surgery and pulmonology.

DOSING MODE

Adults intravaginally: 1 suppository 1 time / day at night; the suppository is inserted into the vagina in the supine position.

Adolescents aged 12 to 18 years suppositories are administered only rectally.

Adults and teenagers over 12 years old rectally: 1 suppository 1 time / day after bowel cleansing.

The treatment regimen is adjusted depending on the severity, stage and duration of the disease. It is possible to prescribe the drug every other day or with interruptions of 2-3 days.

In urology

1 suppository every other day - 10 injections, then after 2-3 days - 10 injections. General course of 20 introductions.

In gynecology

Rectally or intravaginally, 1 suppository after 2 days - 10 injections, then, if necessary, maintenance therapy is prescribed.

In dermatovenereology

1 suppository in 1-2 days - 10-15 injections.

In surgery

1 suppository in 2-3 days - 10 injections.

In pulmonology and phthisiology

1 suppository in 2-4 days - 10-20 administrations.

SIDE EFFECT

The frequency of adverse reactions is classified as follows: very often (≥10%); often (≥1% and<10%); нечасто (≥0.1% и <1%); редко (≥0.01% и <0.1%); очень редко (<0.001%).

Very rarely: local reactions in the form of redness, swelling, itching of the perianal zone, vaginal itching due to individual sensitivity to the components of the drug.

CONTRAINDICATIONS

Pulmonary bleeding and hemoptysis;

Fresh hemorrhage in the vitreous body;

Malignant neoplasms;

Acute renal failure;

Pregnancy;

lactation period;

Children's age up to 12 years (the results of clinical studies are not available);

Hypersensitivity to drugs based on hyaluronidase.

FROM caution and no more than 1 time per week should be used in patients with chronic renal failure, a history of pulmonary bleeding.

PREGNANCY AND LACTATION

The use of the drug during pregnancy and during breastfeeding is contraindicated (clinical experience is not available).

USE FOR LIVER FUNCTION DISTURBANCES

The use of the drug in acute renal failure is contraindicated.

FROM caution and no more than 1 time per week should be used in patients with renal insufficiency.

USE IN CHILDREN

The use of the drug in children under 12 years of age is contraindicated (the results of clinical studies are not available).

SPECIAL INSTRUCTIONS

With the development of an allergic reaction, the use of the drug Longidase ® should be interrupted.

When used against the background of exacerbation of foci of infection to prevent the spread of infection, it is necessary to prescribe the drug Longidase ® under the cover of antimicrobial agents.

Do not use the drug if there are visual signs of its unsuitability (packaging defect, discoloration of the suppository).

In case of skipping the next dose, the drug should be continued as usual (do not double the dose).

If it is necessary to stop taking the drug Longidase ®, cancellation can be carried out immediately, without a gradual dose reduction.

Influence on the ability to drive vehicles and control mechanisms

The use of the drug Longidaza ® does not affect the ability to drive vehicles, maintain mechanisms and other types of work that require an increased concentration of attention and speed of psychomotor reactions.

OVERDOSE

Symptoms overdose can be manifested by chills, fever, dizziness, hypotension.

Treatment: the introduction of the drug is stopped and symptomatic therapy is prescribed.

DRUG INTERACTIONS

Longidase ® can be combined with antibiotics, antiviral, antifungal drugs, bronchodilators.

When administered in combination with other drugs (antibiotics, local anesthetics, diuretics), the possibility of increasing bioavailability and enhancing their action should be considered.

When combined with large doses of salicylates, cortisone, ACTH, estrogens or antihistamines, the enzymatic activity of the drug Longidase ® may be reduced.

Do not use the drug Longidase ® simultaneously with drugs containing furosemide, benzodiazepines, phenytoin.

TERMS AND CONDITIONS OF DISCOUNT FROM PHARMACIES

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, dark place, out of the reach of children, at a temperature of 2° to 15°C. Shelf life - 2 years.

The drug Longidase is a macromolecular complex, which consists of two components: the proteolytic enzyme hyaluronidase and a high-molecular carrier, the role of which in this drug is played by one of the oxides of ethylene piperazine.

The components of Longidase provide the drug with a wide range of therapeutic effects:

immunomodulatory,
decongestant,
anti-inflammatory,
antioxidant,
chelating.

In addition, another important effect of Longidaza is the binding of heavy metals in the body and the overwhelming effect on toxins, due to which this medication is effective for various kinds of intoxication.

Longidaza is available in two dosage forms: suppositories for rectal and vaginal administration, and lyophysilate, from which a solution for injections is prepared subcutaneously or intramuscularly. In this material we will talk about the first of them - suppositories.
Candles Longidase visually represent elongated suppositories with a faint smell of cocoa butter. The color of the candles is yellowish. In the package, suppositories are in individual contour cells of five pieces. One suppository of Longidase contains 3000 international units of a complex of hyaluronidase and a high molecular weight carrier. The price of Longidaza suppositories in Russian pharmacies starts from 1,700 rubles per pack.

Indications for use

In drug protocols for various pathologies, Longidaza suppositories can be used as a component of complex therapy, or as a single monotherapy drug. The main indication for the use of this drug is an excessive neoplasm of the structural elements of the connective tissue - hyperplasia.
Longidase suppositories, despite the rather high price, are a popular drug in six branches of medicine. Let's consider them separately.

The use of Longidaza in gynecology

In gynecological practice, this drug, in most cases, is the main component of the treatment of adhesions that occur as consequences in inflammatory and chronic diseases of the pelvic organs. In addition, Longidase suppositories are used for intrauterine synechia, chronic endomyometritis and tubal-peritoneal infertility.

The use of Longidaza in urology

Longidaza suppositories are used for:

chronic prostatitis - inflammation of the prostate gland of a chronic nature;
interstitial cystitis, also known as painful bladder syndrome;
narrowing of the lumen of the urethra (urethra) and ureters - stricture,
- deformation of the penis due to the growth of fibrous tissue;
benign prostatic hyperplasia at the initial stage.

It is also quite common practice to use Longidaza suppositories for the prevention of scars that may occur after surgery on urological organs.

The use of Longidaza in surgery

In this industry, Longidaza is prescribed in the postoperative period as a therapy or prevention of scars. Also, the drug is used to prevent the development of adhesions after surgery on the abdominal organs, for the treatment of non-healing wounds, trophic ulcers and adhesive disease.

The use of Longidaza in orthopedics

The main indication for the use of Longidaza in orthopedics is joint contracture. This pathology is a limitation of the passive mobility of the joints, provoked by cicatricial contraction of the tendons or skin. In addition, in orthopedic practice, the drug is prescribed for arthrosis, hematomas and Bechterew's disease - a chronic systemic pathology of the joints, which is also called ankylosing spondylitis.

The use of Longidaza in pulmonology and phthisiology

The main pathologies for the treatment of which Longidase suppositories are used in pulmonology and phthisiology are:

infiltrative tuberculosis - a form of tuberculosis characterized by inflammatory changes in the lungs of an exudative nature;
cavernous-fibrous tuberculosis is a form of pathology that is accompanied by the development of a fibrous cavity;
pneumosclerosis - a disease caused by the replacement of lung tissue with connective tissue;
tuberculoma - tuberculosis with a characteristic round formation in the lungs;
alveolitis - infection and subsequent inflammation of the hole in the gum, which is formed after tooth extraction;
pneumofibrosis - respiratory dysfunction caused by an increase in the volume of connective tissue in the lungs;
siderosis - a pathology of the lungs, which is provoked by iron-containing dust deposited in the respiratory system;
pleurisy - an inflammatory disease of the pleural sheets;
Interstitial pneumonia is an inflammatory disease of the lungs, which is characterized by damage to the connective tissue around the alveoli.

The use of Longidaza in dermatovenereology and cosmetology

In most cases, Longidaza suppositories are used in this branch of medicine to combat scars that are the result of injuries of a different nature. Also, this drug is prescribed for:

scleroderma - an autoimmune pathology of the connective tissue, which is manifested by a characteristic skin lesion;
pyoderma - skin lesions of a purulent nature.

Method of application and dosage of suppositories Longidase

Given the fact that Longdaza in the form of suppositories is used in the treatment of many diseases, it is not possible to reduce any generalized tactics for its use. It all depends on the pathology for which the drug is used, the intensity of the course of the disease, the individual characteristics of the patient's body.
As an advisory material, we give exemplary tactics for using Longidaza suppositories for the treatment of pathologies of various groups:

It must be remembered that the above table in no way indicates how Longidase is used. Any appointment of the drug should be carried out by a doctor and self-medication with these medicines is impossible.
We also give the basic rules for using Longidaza candles:

when using the drug rectally, it is necessary to first clean the intestines;
the introduction of suppositories vaginally is carried out while lying on the bed before going to bed;
a second course of using Longidaza is possible only after three months have passed since the completion of the previous one.

Contraindications to the use of Longidaza suppositories

Longidase suppositories are not prescribed in the following cases:

individual hypersensitivity or intolerance to the components of the drug;
severe renal dysfunction;
under the age of twelve;
pregnancy and lactation.

In addition, special care in the use of Longidaza is needed in the acute course of any infectious disease (in such cases, Longidaza is prescribed only in combination with an antimicrobial drug), as well as in the case of patients who have recently suffered serious bleeding of any origin or suffer from from kidney failure.

Side effects from using Longidaza suppositories

When using these suppositories according to the scheme prescribed by the doctor, practically no side effects are observed. There are only a few confirmed cases of allergic manifestations of a local or systemic nature, but no systemic nature was found in their manifestation. Similarly, cases of overdose from the use of Longidaza suppositories have not been recorded.

Many women suffer from chronic diseases of the reproductive system. Treatment of gynecological diseases is quite problematic even for experienced and qualified doctors. This is due to the fact that the places of accumulation of microorganisms that cause inflammation in the organs of the genitourinary system of a woman are difficult to access for sanitation.

The most common breeding sites for pathogenic bacteria in the female body are the posterior fornix of the vagina, the uterine cavity, fallopian tubes, and bladder. Vaginal suppositories "Longidaza" deliver the active ingredient of the drug directly into the vagina, i.e. to the place of localization of pathogenic microorganisms.

General description of the drug

Longidaza is produced in the Russian Federation by NPO Petrovax Pharm LLC. The company is distinguished by consistently high quality of its products. It produces drugs that since 1996 meet all quality guarantees. Longidase is an enzyme agent with proteolytic activity. The active substance of the drug is Bovhyaluronidase azoximer.

This substance is a proteolytic enzyme that breaks down protein molecules and promotes the resorption of contractures, scars and adhesions. The action of Longidase is most effective in the early stages of the pathological process.

In addition to the proteolytic action, the drug has an anti-inflammatory, antioxidant and immunomodulatory effect.

Reasons for using Longidase in gynecology

All inflammatory foci in the human body eventually separate from healthy tissues and organs by the so-called adhesions. Adhesions consist of connective tissue structures that delimit the focus of inflammation and reduce the risk of infection spreading to nearby organs and tissues. In gynecology, the problem of adhesive disease is almost in the first place, since the appearance of adhesions for a woman has ambiguous consequences. In addition to the listed positive properties, connective tissue strands and films also have negative qualities:

Medicines penetrate very poorly through adhesive formations, which increases the recovery time.
Adhesions stick closely spaced organs together. Complications of the adhesive process can be intestinal obstruction, displacement of the uterus, ectopic pregnancy, infertility.

So, adhesions in the fallopian tubes prevent the egg from passing into the uterine cavity after ovulation, which leads to the impossibility of its fertilization and, accordingly, the conception of a child. The drug Longidaza splits the adhesions formed as a result of inflammation, enhances the local effect of other drugs and reduces the treatment time by about one and a half times.

One of the useful properties of the drug is its anti-inflammatory effect. The drug reduces the amount of inflammatory mediators, relieves swelling, improves the transport of nutrients through the interstitial fluid. The drug increases the elasticity of the connective tissue, which reduces the stagnation of blood and lymph in the area of inflammation, reducing pain.

Release forms

The tool is available in two forms:

in the form of suppositories (candles) of 3000 IU;
in the form of a powder in ampoules or in vials (1500 or 3000 IU) for the preparation of an injection solution.

Candles can be administered vaginally or rectally. In gynecology, it is Longidaza suppositories that are in demand.

Indications for use

Gynecological diseases in which the appointment of the drug is indicated include:

Acute salpingo-oophoritis.
Chronic salpingo-oophoritis in the acute stage.
Tubal-peritoneal infertility.
Adhesive disease.
Intrauterine synechia (adhesions between separate parts of the uterine cavity).
Chronic endometritis.
Condition after abortion and miscarriage.

In combination with antibacterial, anti-inflammatory and detoxification therapy, Longidaza Suppositories is especially effective. It enhances the effect of other drugs without interfering with the mechanisms of their work.

Instructions for the use of candles "Longidaza"

The drug in the form of suppositories is applied vaginally in a course of 10 days. Suppositories can be administered daily, every other day and 1 time in three days. The frequency of use of the drug is prescribed by the gynecologist, based on the history of the disease, data from an objective study and the severity of the disease.

If necessary, a second course of treatment is carried out no earlier than 3 months after the previous course.

During menstruation, suppositories should be applied rectally.

The difference between the drug "Longidaza" and other similar ones is that its use is extremely rarely accompanied by side effects. It has been established that only in 0.001% of cases local allergic reactions develop in the form of burning, swelling, vaginal itching or itching of the perianal area.

It was also noted that when using the drug with antihistamines, the therapeutic effect is significantly reduced, so their combined use is undesirable.

Contraindications

The main contraindications to the use of the drug are:

Pregnancy.
Breastfeeding a child.
Allergic reactions to the drug "Longidase" and other pharmacological preparations, which contain a hyaluronidase conjugate.
Oncological diseases.
Severe kidney and liver disease.
Acute infectious diseases.
History of pulmonary hemorrhage.

The use of the drug has not been studied in children under 12 years of age, so Longidase suppositories are not used in the treatment of children of this age.

Summarizing everything that has been said about the drug "Longidaza" in the form of suppositories, we can conclude that this drug is an effective drug in the treatment and prevention of adhesive disease. The correct appointment and use of the drug "Longidaza candles" in gynecology reduces the risk of developing adhesive disease after abortion, intrauterine interventions and chronic inflammatory processes in the woman's small pelvis.

The drug "Longidaza" has good reviews from consumers and gynecologists, it is widely used throughout the post-Soviet space. However, self-medication with Longidaza suppositories is contraindicated; the drug can only be prescribed by a doctor.

In the 90s of the last century, a unique remedy was patented in Russia that can restore female fertility - Longidaza suppositories. It is useful to read the instructions for use in gynecology of this drug for all those women who plan to use it for the treatment and prevention of diseases of the pelvic organs.

The main active ingredient of Longidase is the enzyme hyaluronidase. In addition to it, the composition of suppositories includes azoximer bromide, which protects the active substance from destruction, increases its duration and increases the overall effectiveness of treatment. Suppositories have the following properties:

The active substance does not accumulate in the body, and acts only on the affected areas.

Indications for use Longidase

In gynecology, suppositories are used for the treatment and prevention of:

The tool is used in the complex therapy of infertility that has arisen against the background of obstruction of the fallopian tubes.

Rules for using candles

In gynecological practice, 1 Longidaza suppository is usually prescribed rectally or vaginally 1 time in 3 days for a month. In exceptional cases, doctors increase the standard dosage. So, when identifying advanced forms of diseases, patients are recommended to use candles daily.

When introducing a suppository, you must adhere to the following algorithm of actions:

take care of the cleanliness of the hands and anogenital area;
lie on your side and pull your knees to your chest;
remove the drug from the contour packaging;
insert the drug deep into the anus or vagina.

In order to push the candle to the desired depth, you can use a special applicator. After the procedure, you need to spend at least an hour in bed.

Longidase suppositories can be used simultaneously with antiviral, antibacterial, bronchodilator and antifungal agents. However, it should be borne in mind that suppositories may slightly enhance the pharmacological effect of these drugs.

Means analogues

Longidaza is a rather expensive drug. Therefore, women who have indications for its use very often look for a cheaper replacement for it. The most similar in composition and form analogue of this agent candles with Lidaza are considered- a preparation produced from the testes of livestock. The composition of these suppositories includes hyaluronidase and a complex of excipients that enhance the therapeutic effect of the base component. Candles containing Lidaza have one significant drawback - they are not produced on an industrial scale. Usually they are prepared by pharmacists or pharmacists in pharmacies according to a doctor's prescription.

Such candles are much cheaper than Longidaza. At the same time, they cannot be considered a complete analogue of the original drug: they do not contain a very important component - azoximer bromide. Therefore, if the doctor prescribes Longidase suppositories for the treatment of inflammatory, adhesive or other pathological processes in the pelvic area, then there is no point in experimenting with other drugs. Self-medication can provoke the development of dangerous complications.

Contraindications to the use of candles

Candles Longidaza and their analogues have a number of contraindications. Grounds for refusal to use them may be:

Ignoring contraindications when using suppositories can lead to the most unexpected consequences for the body. Therefore, it is very important to coordinate the use of this drug with your doctor.

A drug with proteolytic activity of prolonged action. Longidase ® is a hyaluronidase conjugate with a poly-1,4-ethylenepiperazine N-oxide derivative. It has enzymatic proteolytic (hyaluronidase) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory action.

A prolonged action is achieved by covalent binding of the enzyme to a physiologically active high molecular weight carrier (an activated derivative of poly-1,4-ethylenepiperazine N-oxide), which has its own pharmacological activity.

Longidase ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and TNFα), increases the humoral immune response and the body's resistance to infection.

The pronounced antifibrotic properties of Longidase are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors: the enzymatic activity of Longidase is preserved when heated to 37°C for 20 days, while native hyaluronidase begins to lose its activity under the same conditions. activity during the day.

Longidase ® provides simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier capable of binding enzyme inhibitors released during hydrolysis of matrix components and stimulators of collagen synthesis (iron, copper, heparin ions). Due to these properties, Longidase ® has not only the ability to depolymerize the connective tissue matrix in fibrous-granulomatous formations, but also to suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

Longidase ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The use of Longidaza in therapeutic doses during or after surgical treatment does not cause a deterioration in the course of the postoperative period or the progression of the infectious process; does not slow down the recovery of bone tissue.

Pharmacokinetics

Suction

When administered rectally, the drug is rapidly absorbed into the systemic circulation and Cmax is reached after 1 hour. The bioavailability of Longidase ® rectal suppositories is at least 70%.

Distribution

The drug is characterized by a high distribution rate: the half-distribution period is about 30 minutes.

Metabolism

The drug penetrates into all organs and tissues (including through the BBB and the hematoophthalmic barrier). Does not accumulate in tissues.

breeding

T 1/2 ranges from 42 to 84 hours. It is excreted mainly by the kidneys.

Release form

Suppositories for vaginal or rectal administration, torpedo-shaped, light yellow in color, with a slight specific smell of cocoa butter, marbling is allowed.

Excipients: cocoa butter.

5 pieces. - cellular contour packings (2) - packs of cardboard.

Dosage

Rectally: 1 suppository 1 time / day after bowel cleansing.

Intravaginally: 1 suppository 1 time / day at night; the suppository is inserted into the vagina in the supine position.

The treatment regimen is adjusted depending on the severity, stage and duration of the disease. It is possible to prescribe the drug every other day or with interruptions of 2-3 days.

In urology

1 suppository every other day - 10 injections, then after 2-3 days - 10 injections. General course of 20 introductions.

In gynecology

Rectally or intravaginally, 1 suppository after 2 days - 10 injections, then, if necessary, maintenance therapy is prescribed.

In dermatovenereology

1 suppository in 1-2 days - 10-15 injections.

In surgery

1 suppository in 2-3 days - 10 injections.

In pulmonology and phthisiology

1 suppository in 2-4 days - 10-20 administrations.

Overdose

Data on drug overdose are not provided.

Interaction

When using Longidaza in patients receiving salicylates, cortisone, ACTH, estrogens or antihistamines in high doses, the effectiveness of the hyaluronidase enzyme may be reduced.

When prescribing in combination with other drugs, the possibility of increasing their absorption (bioavailability) and enhancing systemic action should be considered.

Side effects

Rarely: allergic reactions with increased individual sensitivity.

Indications

In urology:

chronic prostatitis;
interstitial cystitis;
strictures of the urethra and ureters;
Peyronie's disease;
the initial stage of benign prostatic hyperplasia;
prevention of scarring and strictures after surgical interventions on the urethra, bladder, ureters.

In gynecology:

prevention and treatment of adhesions in the pelvis in chronic inflammatory diseases of the internal genital organs;
prevention and treatment of adhesions in the small pelvis after gynecological manipulations (including induced abortions, previous surgical interventions on the pelvic organs);
intrauterine synechia;
tubal-peritoneal infertility;
chronic endomyometritis.

In dermatovenereology:

limited scleroderma;
prevention of fibrotic complications of sexually transmitted infections.

In surgery:

prevention and treatment of adhesions after surgical interventions on the abdominal organs;
long-term non-healing wounds.

In pulmonology and phthisiology:

pneumofibrosis;
siderosis;
tuberculosis (cavernous-fibrous, infiltrative, tuberculoma);
interstitial pneumonia;
fibrosing alveolitis;
pleurisy.

To increase the bioavailability of antibiotic therapy in urology, gynecology, dermatovenereology, surgery and pulmonology.

Contraindications

malignant neoplasms;
pregnancy (clinical experience is absent);
children under 12 years of age (the efficacy and safety of the drug have not been studied);
hypersensitivity to the drug;
increased individual sensitivity to drugs with hyaluronidase activity.

Use with caution and not more than once a week in patients with renal insufficiency, a history of pulmonary bleeding.

Application features

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy.

Data on the safety of the drug during lactation is not provided.

Longidase has no embryotoxic and teratogenic effects.

Application for violations of kidney function

Use with caution and not more than once a week in patients with renal insufficiency.

special instructions

When used against the background of exacerbation of foci of infection to prevent the spread of infection, prescribe under the cover of antimicrobial agents.

With the development of an allergic reaction, the use of Longidaza should be immediately interrupted.